Research consortium produces high-resolution 3-D map of GLP-1R

May 18, 2017, ShanghaiTech University
Structures of human GLP-1 and glucagon receptors, important drug targets for diabetes and obesity. Credit: ShanghaiTech University

An international team led by the iHuman Institute, ShanghaiTech University determined the molecular structure of the human glucagon-like peptide-1 receptor (GLP-1R). The results, described in the paper entitled "Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators," appears May 17, 2017 in the journal Nature. This study is published together in Nature with a companion paper led by colleagues at the Shanghai Institute of Materia Medica (SIMM) describing the full length glucagon receptor.

GLP-1R is a well-recognized drug target for type 2 diabetes, exemplified by several peptidic therapeutic agents on the market, with combined sales of several billions of dollars each year. Worldwide, the costs associated with treating diabetes and its complications are estimated to exceed $200 bn a year. Diabetes is growing at an alarming rate throughout the world, with the most significant and recent growth occurring in China.

The GLP-1R structure was determined in complex with negative allosteric modulators (NAMs). The NAMs block the activation of GLP-1R by inserting into the cavity between helices VI and VII, while PAMs bind mainly to the space between helices V and VI enabling the activation. "This structure is one of the holy grails of GPCR drug discovery," said Professor Raymond Stevens at the iHuman Institute, ShanghaiTech University who co-led the study.

Orally available small molecule therapeutics have been vigorously sought after by many pharmaceutical companies for several decades to replace the peptides. "GPCRs that bind peptides can be particularly challenging for small molecule drug discovery given multiple points of connection," said iHuman Associate Professor Gaojie Song.

"This major undertaking started in 2002 when we were looking for small molecule GLP-1R agonists," said Professor Ming-Wei Wang of SIMM and Fudan University who co-led the study. "Our failed efforts in making the first orally active GLP-1R agonist Boc5 led us to conclude that high resolution structural biology is the preferred solution to drugability."

Explore further: Scientists decipher the multi-domain, full-length structure of the human smoothened receptor

More information: Gaojie Song et al. Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators, Nature (2017). DOI: 10.1038/nature22378

Related Stories

A look at the 'marijuana' receptor

October 20, 2016

Researchers have the clearest picture yet of the receptor that causes the "high" associated with marijuana. The three-dimensional image of cannabinoid receptor 1, revealed October 20 in Cell, reveals how molecules like THC ...

Scientists find 3D structure of key drug target for diabetes

July 17, 2013

An international team led by scientists at The Scripps Research Institute (TSRI) has determined and analyzed the three-dimensional atomic structure of the human glucagon receptor. The receptor, found mainly on liver and kidney ...

Recommended for you

New theory shows how strain makes for better catalysts

April 20, 2018

Brown University researchers have developed a new theory to explain why stretching or compressing metal catalysts can make them perform better. The theory, described in the journal Nature Catalysis, could open new design ...

Machine-learning software predicts behavior of bacteria

April 19, 2018

In a first for machine-learning algorithms, a new piece of software developed at Caltech can predict behavior of bacteria by reading the content of a gene. The breakthrough could have significant implications for our understanding ...

Spider silk key to new bone-fixing composite

April 19, 2018

UConn researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

GLUT5 fluorescent probe fingerprints cancer cells

April 19, 2018

Determining the presence of cancer, as well as its type and malignancy, is a stressful process for patients that can take up to two weeks to get a diagnosis. With a new bit of technology—a sugar-transporting biosensor—researchers ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.